Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 25Neoplasms 9Kidney Neoplasms 8Prostatic Neoplasms 6Carcinoma, Non-Small-Cell Lung 6Carcinoma, Hepatocellular 6Colorectal Neoplasms 4Carcinoma, Medullary 4Carcinoma 4Triple Negative Breast Neoplasms 2Thyroid Neoplasms 2Pain 2Ovarian Neoplasms 2Liver Neoplasms 2von Hippel-Lindau Disease 1Urologic Neoplasms 1Thyroid cancer, follicular 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Mesothelioma 1Melanoma 1Kidney Diseases 1Head and Neck Neoplasms 1Glioma 1Glioblastoma 1

Interventions

Sunitinib 4avelumab 2Axitinib 2trifluridine tipiracil drug combination 1trebananib 1palbociclib 1cabozantinib 1atezolizumab 1VMBP protocol 1Plasma Exchange 1Pharmaceutical Preparations 1Paclitaxel 1Nivolumab 1Cystoscopy 11-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Kidney Diseases × cabozantinib × Clear all
NCT04300140 2023-10-30

Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma

Aravive, Inc.

Phase 1/2 Terminated
72 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡